Newly FDA-approved Revtorpyk wins NCCN listing
Celcuity (NASDAQ: CELC) said its Revtorpyk (gedatolisib) plus fulvestrant, with or without palbociclib, was added to NCCN Guidelines as a preferred Category 1 option for HR+, HER2- advanced or metastatic breast cancer after endocrine therapy progression. FDA approved Revtorpyk on July 14, 2026 for HR+/HER2- disease without detected PIK3CA mutation.
How this was made
The 30-second read
Why it matters
A preferred NCCN Category 1 recommendation for second-line and/or subsequent-line use can strengthen physician adoption and support commercial traction for Celcuity’s regimen.
Market read
Guideline endorsement is a tangible catalyst for oncology drug adoption, but the article lacks quantitative commercial or clinical performance details.
What to watch
The article does not address Revtorpyk’s current utilization, pricing/reimbursement, safety/tolerability in practice, or competitive positioning versus other second-line options.
Background
Revtorpyk (gedatolisib) received FDA approval on July 14, 2026 for HR+/HER2- locally advanced or metastatic breast cancer without a detected PIK3CA mutation after endocrine therapy progression.
Ticker impact
Celcuity says Revtorpyk (gedatolisib) is recommended by NCCN as a preferred Category 1 second-line and/or subsequent-line therapy after endocrine progression.
Moderate positive bias for near-term sentiment, with follow-through dependent on uptake and any additional commercial or clinical updates.
The article discloses a concrete guideline inclusion and ties it to a specific FDA-approved indication, but it provides no sales, trial readouts, or financial guidance to quantify impact.
Market effects
Reinforces the clinical and commercial momentum for PI3K/mTOR pathway inhibitors in HR+/HER2- metastatic breast cancer post-endocrine therapy.
Primarily US oncology guideline and reimbursement signaling.
Could support international adoption narratives, though the article is US FDA and NCCN specific.
Counterpoint
NCCN inclusion does not guarantee rapid uptake; real-world adoption may lag due to formulary status, prior authorization, and clinician familiarity.
Key entities
- companyCelcuity
US biotech announcing NCCN Category 1 guideline recommendation for Revtorpyk plus fulvestrant, with or without palbociclib.
- drugRevtorpyk (gedatolisib)
PI3K isoform and mTOR inhibitor regimen recommended by NCCN for specified HR+/HER2- metastatic breast cancer after endocrine progression.
- regulatory/clinical guideline bodyNCCN Guidelines
Clinical practice guidelines that designate Revtorpyk regimen as preferred Category 1 second-line and/or subsequent-line therapy.
- regulatory agencyFDA
Approved Revtorpyk on July 14, 2026 for the specified HR+/HER2- indication.
